Abpro Holdings Reports Improved Net Loss of $940,000 in Q2 2026

Abpro Holdings, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $940,000, a significant improvement compared to a net loss of $2.98 million in the same period of 2025. The company did not generate any revenue during the quarter, consistent with the previous year. Total operating expenses decreased by 48% to $1.175 million, down from $2.261 million, primarily due to reduced research and development costs as the majority of personnel were furloughed or terminated in late 2025. General and administrative expenses also fell by 40% to $1.166 million, reflecting cost-cutting measures implemented in the latter half of 2025.

For the first half of 2026, Abpro reported a net loss of $1.968 million, compared to a net loss of $6.871 million for the same period in 2025. Total operating expenses for the six months ended June 30, 2026, were $2.108 million, a 60% decrease from $5.219 million in the prior year. The reduction in expenses was attributed to the same factors affecting the quarterly results, including a significant decrease in research and development activities while the company sought additional capital to resume operations.

Abpro's financial position showed a notable increase in cash reserves, with $4.236 million reported as of June 30, 2026, compared to $67,000 at the end of 2025. This increase was primarily due to financing activities, which provided $7.288 million in cash during the first half of 2026, largely from the issuance of common stock under the Standby Equity Purchase Agreement (SEPA). However, the company also reported current liabilities of $8.225 million, indicating that its cash reserves may not be sufficient to sustain operations for the next 12 months without additional funding.

Strategically, Abpro's stock was delisted from the Nasdaq and is now trading on the OTC Pink Limited Market under the ticker "ABPO." The delisting followed the company's failure to meet Nasdaq's minimum equity standards. While the company continues to pursue its research and development programs, it faces challenges in raising capital due to the delisting, which may impact liquidity and market price of its common stock. The company has expressed substantial doubt regarding its ability to continue as a going concern within the next year unless it can secure additional funding through equity or debt financing, collaboration agreements, or research grants.

Looking ahead, Abpro plans to continue fundraising efforts and explore alternative revenue streams from collaboration and licensing agreements. The company is focused on advancing its pipeline of antibody therapeutics, particularly in immuno-oncology and ophthalmology, but acknowledges that its future viability is contingent on its ability to raise sufficient capital to support ongoing operations and development activities.